The Vanta Bioscience IPO date has been confirmed to have started on September 25, 2017 and ended on September 27, 2017.
Using an IPO, Vanta Bioscience is seeking to raise Rs 7.56 crore. Its price is ₹50 per share and the minimum lot size for an application is 3000 shares. The minimum amount of investment required by retail investors is ₹150,000.
Start your investing journey today. How do you open your own demat account for free?
Bidding Dates
September 25-27
Price Range
₹50 per share
Face Value
₹10 per share
GMP
₹47.14
Vanta Bioscience IPO GMP
The Vanta Bioscience Limited IPO GMP is ₹47.14.
IPO Overview
Vanta Bioscience’s initial public offering (IPO) has a set price of Rs 7.56 crore. The IPO auction for Vanta Bioscience began on September 25, 2017 and ended on September 27, 2017. On October 6, 2017, the shares were listed on the BSE SME. The IPO price for Vanta Bioscience is $50 per share. A lot size of 3000 shares is required for an application. Retail investors must make a minimum investment of $150,000 to participate.
VBL provides a variety of in vitro (cell, tissue, and organism) and in vivo (animal) toxicity investigations for its diversified clients in accordance with various regulatory standards from across the world. Toxicology is the study of the harmful effects of chemicals on living creatures. It is a field of biology, chemistry, and pharmacology. It also investigates the adverse effects of chemical, biological, and physical agents in biological systems in order to determine the level of damage to living creatures.
In toxicology, the link between dose and its effects on the exposed organism is extremely important. Toxicology and risk assessment are sometimes used interchangeably and are thought to be synonymous. Vanta Bioscience is headquartered in Des Moines, Iowa, with offices in Brussels, Belgium, and West Des Moines, Iowa. In Chennai, India, there is a toxicology research centre.
Vanta Bioscience IPO Details
| IPO Date | September 25, 2017 to September 27, 2017 |
| Listing Date | October 6, 2017 |
| Face Value | ₹10 per share |
| Price | ₹50 per share |
| Lot Size | 3000 Shares |
| Total Issue Size | 1,512,000 shares (aggregating up to ₹7.56 Cr) |
| Issue Type | Fixed Price Issue IPO |
| Listing At | BSE SME |
Vanta Bioscience IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 3000 | ₹150,000 |
| Retail (Max) | 1 | 3000 | ₹150,000 |
Vanta Bioscience IPO Listing Details
| Listing Date | October 6, 2017 |
| BSE Script Code | 540729 |
| NSE Symbol | |
| ISIN | INE695X01011 |
| Final Issue Price | ₹50 per share |
Company Profile
Vanta Bioscience Ltd. (VBL), founded in 1995, is a preclinical contract research organisation that provides safety assessment services to clients in the pharmaceutical, medical device, nutraceuticals, feed additive, biotech, agrochemicals, cosmetics, and chemical industries. Furthermore, they provide risk assessment services for analysing the safety of active pharmaceutical ingredients (API), excipients, and extractable and leachable pharmaceutical contaminants emerging from the production process or product degradation. VBL also provides
expert assistance for pharmaceutical producers in determining health-based exposure limits (e.g., permitted daily exposure (PDE) or allowed daily exposure (ADE), as well as occupational exposure limits (OEL). Toxicology, batch release tests, biocompatibility investigations, chemical safety, and diet formulation are among their services.
Registrar Info
| Name | Bigshare Services Pvt Ltd |
| Phone number | +91-22-6263 8200 |
| Email ID | ipo@bigshareonline.com |
| Website | ipo.bigshareonline.com |
Contact Details
| Name | Vanta Bioscience Ltd |
| Phone number | +91 40 6657 5454 |
| Email ID | info@vantabio.com |
| Website | vantabio.com |
IPO Strenghts
- Experienced promoters and a competent management team.
- Well-established relationships with a loyal customer base.
- Access to markets worldwide, enabling global reach.
IPO Weakness
- Heavy reliance on customers based in the United States.
- Need to adhere to multiple laws and regulations in these countries to ensure compliance.
- Competition from other players in the market.
